# Phase 2 ovarian cancer trials recruiting: 113 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 113 trials in phase 2 for ovarian cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 ovarian cancer trials: 113 rows for $5.65, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/ovarian-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 113
- Recruiting or not yet: 113
- Read on: November 19, 2026

## Trials

The 25 newest of 113, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07940062 | Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management | British Columbia Cancer Agency | Phase 2 | Not yet recruiting | Co-existent Endometrial and Ovarian Carcinoma, Ovarian Carcinoma, Endometrial Carcinoma (EC) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940062) |
| November 12, 2026 | NCT07934121 | MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer | Tongji Hospital | Phase 2 | Not yet recruiting | Platinum-Sensitive Recurrent Ovarian Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934121) |
| September 28, 2026 | NCT07843303 | Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843303) |
| September 21, 2026 | NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial | Dana-Farber Cancer Institute | Phase 2 | Not yet recruiting | Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832227) |
| September 11, 2026 | NCT07815704 | Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | University of Colorado, Denver | Phase 2 | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815704) |
| August 20, 2026 | NCT07776171 | Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC) | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776171) |
| August 5, 2026 | NCT07747506 | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | Verastem, Inc. | Phase 2 | Not yet recruiting | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747506) |
| July 22, 2026 | NCT07720180 | Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide... | Medical University of South Carolina | Phase 2 | Not yet recruiting | Ovarian Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720180) |
| July 22, 2026 | NCT07718854 | Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer | Tufts Medical Center | Phase 2 | Recruiting | Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer, Recurrent Ovarian Clear Cell Adenocarcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718854) |
| July 20, 2026 | NCT07714668 | A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 | Recruiting | Ovarian Cancer, Recurrent Ovarian Cancer | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714668) |
| June 29, 2026 | NCT07673835 | Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II） | Obstetrics & Gynecology Hospital of Fudan University | Phase 2 | Not yet recruiting | Ovarian Cancer | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673835) |
| June 25, 2026 | NCT07667751 | An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Ovary Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667751) |
| June 23, 2026 | NCT07663513 | Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer | Fudan University | Phase 2 | Not yet recruiting | Ovarian Cancers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663513) |
| June 16, 2026 | NCT07652073 | A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer | Danatlas Pharmaceuticals Co., Ltd | Phase 2 | Not yet recruiting | Advanced or Metastatic Ovarian Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652073) |
| June 15, 2026 | NCT07647653 | Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer | Shandong University | Phase 2 | Not yet recruiting | Ovarian Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647653) |
| June 8, 2026 | NCT07634094 | Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Ovarian Cancer | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634094) |
| June 8, 2026 | NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631871) |
| May 18, 2026 | NCT07591831 | Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591831) |
| May 14, 2026 | NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or... | Peking University People's Hospital | Phase 2 | Recruiting | Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586826) |
| March 27, 2026 | NCT07495124 | IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence | University of Washington | Phase 2 | Recruiting | Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495124) |
| March 24, 2026 | NCT07489300 | Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489300) |
| March 6, 2026 | NCT07454018 | Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454018) |
| March 3, 2026 | NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | University of California, Irvine | Phase 2 | Recruiting | Breast Cancer, Sarcoma, Gastric (Stomach) Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447050) |
| March 3, 2026 | NCT07446049 | A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the... | Convalife (Shanghai) Co., Ltd. | Phase 2 | Not yet recruiting | Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446049) |
| February 12, 2026 | NCT07407452 | Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and... | Jiangsu Cancer Institute & Hospital | Phase 2 | Not yet recruiting | Ovarian Cancers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407452) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 4 |
| Fudan University | 4 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 3 |
| Obstetrics & Gynecology Hospital of Fudan University | 2 |
| The University of Hong Kong | 2 |
| Medical University of South Carolina | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| Roswell Park Cancer Institute | 2 |
| Dana-Farber Cancer Institute | 2 |
| British Columbia Cancer Agency | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| University of Colorado, Denver | 2 |
| Sun Yat-sen University | 2 |
| University of California, Irvine | 2 |
| Beijing Biostar Pharmaceuticals Co., Ltd. | 2 |
| Shandong University | 2 |
| University of Alabama at Birmingham | 2 |
| M.D. Anderson Cancer Center | 2 |
| Chongqing University Cancer Hospital | 1 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |
| ARCAGY/ GINECO GROUP | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Instituto Nacional de Cancerologia de Mexico | 1 |
| Institut du Cancer de Montpellier - Val d'Aurelle | 1 |
| Danatlas Pharmaceuticals Co., Ltd | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 47 |
| China | 35 |
| Spain | 15 |
| South Korea | 14 |
| France | 13 |
| Italy | 10 |
| Canada | 9 |
| Belgium | 7 |
| United Kingdom | 7 |
| Australia | 7 |
| Japan | 5 |
| Germany | 5 |
| Taiwan | 4 |
| Israel | 3 |
| Poland | 3 |
| Norway | 3 |
| Switzerland | 3 |
| Denmark | 3 |
| Puerto Rico | 3 |
| Hong Kong | 2 |
| Turkey (Türkiye) | 2 |
| Austria | 2 |
| Netherlands | 2 |
| Czechia | 2 |
| Singapore | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Land surveyors in the United States](https://specstream.ai/data/businesses/land-surveyors/united-states)
- [Cajun and Creole restaurants in the United States](https://specstream.ai/data/businesses/cajun-and-creole-restaurants/united-states)
- [Salad bars in the United States](https://specstream.ai/data/businesses/salad-bars/united-states)
- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
- [Awning suppliers in the United States](https://specstream.ai/data/businesses/awning-suppliers/united-states)
- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
